mRNA science has shown the power of using an operating system framework for drug discovery and development with the successful COVID vaccine developments from Pfizer and Moderna. Integrating technology into the drug design process introduces unparalleled speed and flexibility. Kuano is using AI, quantum chemistry, and medical science to focus on enzyme reactions, a key factor in drug development, to develop novel therapeutics. The company is able to model enzyme reactions with unprecedented specificity allowing the drug makers to acquire the building blocks for pharmaceuticals that will address some of our most pressing and challenging diseases. London TechWatch caught up with Cofounder and CEO Vid Stojevic to learn more about how the Kuano changes the paradigm of drug development, the company’s strategic plans, and recent round of funding from ACF Investors, o2h Ventures, and a syndicate of Cambridge, London and UK-based angel investors.
Meat analogues are meat-like substances usually made from plants. These substitutes are growing in popularity thanks to brands like Impossible Burger and Beyond Meat. However, for meat enthusiasts, these substitutes often lack the feel, look, and taste of the real thing. Hoxton Farms is looking to produce real animal fat without harming animals for use in meat alternatives by extracting fat cells. Using cultivated fats has the potential to relieve pressure on the environment caused by factory farms including helping with antibiotic resistance and climate change. The company uses machine learning and mathematical modeling to build its cultured fats with plans to build a scalable prototype within the next 18 months. London TechWatch caught up with Cofounder Ed Steele to learn more about the work to make meat alternatives viable at scale, the company’s future plans, and recent round of funding from investors that include Founders Fund, BACKED VC, Presight Capital, CPT Capital, Sustainable Food Ventures, and others.
Prokarium is developing Vesibax, an innovative, safe, and effective microbial immunotherapy (MI) for early-stage bladder cancer, a disease with afflicts over 550,000 individuals globally every year. CEO Ted Fjallman to learn more about Prokarium’s upcoming pipeline of novel therapies, its current focus, and recent funding round from investors that include Korea Investment Partners (KIP), Flerie Invest, Riyadh Valley Company (RVC), and the UK Government’s Future Fund.
Pitch decks come in a lot of flavors. We’ve seen five pages, we’ve seen fifty. We’ve seen them sparsely punctured with bullet points, we’ve seen what might have happened if David Foster Wallace wrote a novel in PowerPoint. Where’s the golden mean? What can you throw away and what sparks joy?